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WHO’s Response to Global Public 
Health Threats: XDR-TB
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(This letter appears in response to the May 2007 PLoS 
Medicine Editorial: “How Is WHO Responding to Global 
Public Health Threats?” [1])
The travels of a patient with extensively drug-resistant 
tuberculosis (XDR-TB) from North America to Europe and 
back have heightened concerns about this growing global 
disease problem and the possibility of its international 
transmission through travel. The seriousness of this possibility 
raises the question of whether XDR-TB cases or outbreaks 
may constitute public health emergencies of international 
concern (PHEICs) under the 2005 International Health 
Regulations (IHR 2005), which became binding international 
law on June 15, 2007 [2]. XDR-TB may be the ﬁ  rst case of a 
public health problem that tests how States Parties and the 
World Health Organization (WHO) apply the IHR 2005. 
We believe that cases or outbreaks of XDR-TB would meet 
the notiﬁ  cation criteria of the IHR 2005 as events that may 
constitute a PHEIC because they trigger afﬁ  rmative answers to 
at least two of the four questions in the IHR 2005’s decision 
instrument (Annex 2, [3]). Thus, as of June 15, 2007, States 
Parties must report such cases or outbreaks to WHO pursuant 
to the IHR 2005. 
XDR-TB triggers an afﬁ  rmative answer to the decision 
instrument’s question: “Is the public health impact of the 
event serious?”, both because of the possibility of the event 
having a high public health impact and, in many instances, 
the need for external assistance in managing cases. XDR-
TB cases would likely produce an afﬁ  rmative answer to the 
question: “Is the event unusual or unexpected?”, because 
of the higher than expected case-fatality rates, particularly 
where XDR-TB occurs with high prevalence of HIV infection. 
The disease also may generate a positive answer to the 
question: “Is there a signiﬁ  cant risk of international travel 
or trade restrictions?”, primarily because of the possibility of 
international media attention. 
At present, XDR-TB would arguably not produce a clearly 
afﬁ  rmative answer to the question: “Is there a signiﬁ  cant 
risk of international spread?”, because epidemiological data 
linking XDR-TB outbreaks and cases with the international 
movement of people are weak. Experience with TB, multi-
drug-resistant TB (MDR-TB), and XDR-TB demonstrates, 
however, that cross-border spread is a very real threat. XDR-
TB has already spread from one province to several provinces 
in South Africa, and has in all likelihood crossed African 
borders, but conﬁ  rmation is delayed because of inadequate 
surveillance capabilities. 
It remains less certain whether the WHO Director-General 
would determine that XDR-TB cases or outbreaks notiﬁ  ed 
to WHO would constitute a PHEIC. This would lead to the 
issuance of temporary recommendations to States Parties, 
which could include travel restrictions and use of compulsory 
measures such as quarantine or isolation. In February 2007, 
the WHO Global Task Force on XDR-TB argued against such 
a position because “the new regulations are aimed particularly 
to situations where there is a signiﬁ  cant risk of international 
spread” and that temporary recommendations “are really 
intended for outbreaks of acute disease, rather than the 
‘acute-on-chronic’ situation of MDR-TB and XDR-TB” [4]. 
The Global Task Force stated that, if international 
spread of XDR-TB were demonstrated, then standing 
recommendations should be considered. To some extent, 
the recommendations and alerts WHO has already issued on 
XDR-TB suggest that treating XDR-TB as a routine public 
health risk is not adequate. In addition, the IHR 2005 does 
not limit its scope of application to “acute disease” [5]. 
TB has never been an acute risk in the same manner as a 
pandemic strain of inﬂ  uenza, but history attests to TB’s 
persistence as a lethal global threat, especially for vulnerable 
populations.
As the global XDR-TB problem becomes more severe, 
more robust and drastic public health actions may be 
required nationally and globally, including a declaration 
from the WHO Director-General of the existence of a 
PHEIC. A window of opportunity may exist now for effective 
international action to control the spread of the disease, and 
the IHR 2005 may provide a mechanism to help achieve this 
objective. A narrow, limited reading of the IHR 2005’s scope 
of application could undermine its ability to contribute to this 
global health crisis.  
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